RXi Pharmaceuticals Corporation (NASDAQ:RXII) Receiving Somewhat Favorable Press Coverage, Analysis Shows

Media headlines about RXi Pharmaceuticals Corporation (NASDAQ:RXII) have been trending somewhat positive on Monday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. RXi Pharmaceuticals Corporation earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.7980575802707 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:

• Is RXi Pharmaceuticals Corporation (NASDAQ:RXII) Ready for a … – FLBC News (flbcnews.com)
• RXi Pharmaceuticals Corporation (NASDAQ:RXII) Scheduled to Post Earnings on Thursday (americanbankingnews.com)
• Delving Into The Numbers For Rxi Pharmaceuticals Corp (RXII) – Financial News Review (finnewsreview.com)
• RXi Pharmaceuticals Corporation (RXII) closes with a move of -1.35%, PAVmed Inc. (PAVM) noted a price change of … – Stocks Gallery (stocksgallery.com)
• RXi Pharmaceuticals Granted 180-Day Extension by Nasdaq Stock Market to Regain Compliance with Listing … – PR Newswire (press release) (prnewswire.com)

Shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII) remained flat at $0.57 during mid-day trading on Monday. The stock had a trading volume of 149,305 shares. RXi Pharmaceuticals Corporation has a one year low of $0.51 and a one year high of $2.93. The stock’s 50-day moving average is $0.63 and its 200-day moving average is $0.67. The stock’s market capitalization is $12.61 million.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) last released its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.08. Equities research analysts anticipate that RXi Pharmaceuticals Corporation will post ($1.77) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was reported by [[site]] and is owned by of [[site]]. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at [[permalink]].

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.